miR-15a: A Potential Diagnostic Biomarker and a Candidate for Non-operative Therapeutic Modality for Age-related Cataract.

miR-15a: A Potential Diagnostic Biomarker and a Candidate for Non-operative Therapeutic Modality for Age-related Cataract. Br J Biomed Sci. 2019 Jul 02; Authors: Abdullah OA, El Gazzar WB, Salem TI, Elmohamady MN, Nasif SN, Eltaher SM Abstract INTRODUCTION: In order to better understand the role of hsa-miR-15a in the pathogenesis of age-related cataracts, we hypothesised altered expression, and of target anti-apoptotic genes, BCL-2 and MCL-1, in lens epithelial cells amongst age-related cataract patients. MATERIAL AND METHODS: Reverse transcription quantitative polymerase chain reaction (RT-qPCR) quantified the expression of hsa-miR-15a and the target genes BCL-2 and MCL-1 in lens epithelial cells of 120 age-related cataract patients (40 patients with cortical cataracts, 40 patients with nuclear cataracts and 40 patients with posterior subcapsular cataracts) and 40 controls. Sixty specimens (15 normal and 45 cataracts) were stained immunohistochemically with BCL-2 and MCL-1 markers. RESULTS: The expression of hsa-miR-15a was significantly increased (p=0.003) in lens epithelial cells of cataract patients compared to the control group. BCL-2 &MCL-1 expression levels were significantly decreased in cataract patients (p
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research

Related Links:

Conditions:   Dry Eye;   Cataract Surgery;   Patient Related Outcome Measures;   Patient Satisfaction Interventions:   Drug: AEONTM Repair;   Other: Routine post-operative eye drops used. Sponsors:   Guy's and St Thomas' NHS Foundation Trust;   City, University of London;   King's College London Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Glaucoma;   Congenital Cataract Intervention:   Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Dry Eye;   Cataract Surgery;   Patient Related Outcome Measures;   Patient Satisfaction Interventions:   Drug: AEONTM Repair;   Other: Routine post-operative eye drops used. Sponsors:   Guy's and St Thomas' NHS Foundation Trust;   City, University of London;   King's College London Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Glaucoma;   Congenital Cataract Intervention:   Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Dry Eye;   Cataract Surgery;   Patient Related Outcome Measures;   Patient Satisfaction Interventions:   Drug: AEONTM Repair;   Other: Routine post-operative eye drops used. Sponsors:   Guy's and St Thomas' NHS Foundation Trust;   City, University of London;   King's College London Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Glaucoma;   Congenital Cataract Intervention:   Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: This update of the I blood group system (Cooling L. Polylactosamines, there's more than meets the "Ii": a review of the I system. Immunohematology 2010;26:133-55) continues to show the Ii antigens to be increasingly recognized as important posttranslational modifiers regulating cell adhesion, signaling, differentiation, and cancer. Ii antigens can modulate the immune response through the galectin lattice, as well as influence specific protein-protein interactions. Changes in GCNT2 and I expression accompany stem cell differentiation and are associated with tumor progression in melanoma and breast and...
Source: Immunohematology - Category: Hematology Tags: Immunohematology Source Type: research
Abstract Zellweger spectrum disorders (ZSD) constitute a group of rare autosomal recessive disorders characterized by a defect in peroxisome biogenesis due to mutations in one of 13 PEX genes. The broad clinical heterogeneity especially in late-onset presenting patients and a mild phenotype complicates and delays the diagnostic process. Here, we report a case of mild ZSD, due to novel PEX1 variants. The patient presented with an early hearing loss, bilateral cataracts, and leukodystrophy on magnetic resonance (MR) images. Normal results of serum very-long-chain fatty acids (VLCFA) and phytanic acid were found. Mol...
Source: J Appl Genet - Category: Genetics & Stem Cells Authors: Tags: J Appl Genet Source Type: research
Abstract BACKGROUND: In 2019 the German Commission for the Prevention of Blindness (DKVB) held an eye camp in the Tanzanian town of Sumbawanga. For patients with mature cataracts and the ability to see light cateracts were treated by manual small incision cataract surgery (MSICS). For the first time in this camp the quality of the results of the cataract operations was measured. OBJECTIVE: The quality of the cataract operations is presented and the results were assessed in the context of the guidelines of the World Health Organization (WHO). METHODS: Those patients who had a cataract operation in th...
Source: Der Ophthalmologe - Category: Opthalmology Authors: Tags: Ophthalmologe Source Type: research
Conditions:   Inflammation Corneal;   Pain, Postoperative Intervention:   Drug: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL Sponsor:   Oculis Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biomedical Science | Cataracts | Genetics | Laboratory Medicine | Science | UK Health